Xiaflex is also being developed for hammer toe, a common foot deformity where the toe bends abnormally at the middle joint, causing it to curl downward like a hammer, and completed a proof-of-concept study last year with a phase 3 trial due to start in the fourth quarter of this year
Cost advantages are significant, with IV therapy ranging $800-$4800+ monthly versus lower-priced oral supplements
The bacteria can then degrade the peptide itself, altering its structure and rendering it useless
The meta-analysis of the ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony, PIONEER 6, REWIND and AMPLITUDE-O trials shows that the extent of HbA 1c reduction may serve as a proxy for the renal benefits of GLP-1RA therapy
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat